insights_auto
Outlook: 34.5% bullish·20.7% bearish
Go to analysischevron_right
BNTX:NASDAQ
BioNTech SE - ADR
$89.39
arrow_upward
+1.92%(+1.68) 1D
Oct 19, 3:42:36 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$88.10
High
$89.80
Low
$87.72
Mkt. cap
22.46B
Avg. vol.
965.98K
Volume
943.22K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.54
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
Open
$88.10
High
$89.80
Low
$87.72
Mkt. cap
22.46B
Avg. vol.
965.98K
Volume
943.22K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.54
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
Zacks
·
5 hours ago
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch
Stock Titan
·
8 hours ago
BioNTech (BNTX) will present first results for two cancer drug combinations
The Motley Fool
·
1 day ago
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?
The Motley Fool
·
2 days ago
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR